Is Suboxone Addicting?
Reviewed by Josie Desmarais, PMHNP-BC · Board-Certified Psychiatric-Mental Health Nurse Practitioner · Last updated August 2026
The honest answer requires separating two concepts that most people — including many outside the medical field — conflate: physical dependence and addiction. Taking Suboxone daily will produce physical dependence, meaning stopping abruptly causes withdrawal. That is expected, physiologically predictable, and is not addiction. Addiction — compulsive use of a substance despite serious harm — is rare with buprenorphine taken as prescribed. The evidence from decades of research and multiple Cochrane reviews is unambiguous: for most people with opioid use disorder, Suboxone significantly reduces illicit opioid use, overdose death, and harm. The relevant comparison is not Suboxone versus nothing. It is Suboxone versus continued fentanyl exposure in a street drug supply where one dose can be fatal.
Short answer: Medication-assisted treatment combines FDA-approved medication with clinical support. A psychiatric provider can assess whether it is right for you and manage it safely.
Used correctly within medication-assisted treatment, Suboxone reduces harm rather than causing it.
Physical Dependence vs. Addiction: Why the Distinction Matters
These two terms are often used as synonyms, but they describe entirely different phenomena — and conflating them causes real harm to people seeking treatment.
Physical dependence means your body has adapted physiologically to the presence of a substance. Remove it abruptly, and your body reacts with withdrawal symptoms. Physical dependence develops with many medications that carry no addiction potential: beta-blockers, SSRIs, corticosteroids, and blood pressure medications all produce physical dependence. Nobody argues those medications should be avoided because “you’ll become dependent on them.” For more on this, see our guide to whether Suboxone shows up on a drug test.
Taking Suboxone daily will produce physical dependence. This is not a failure of the medication or of the person taking it. It is a predictable pharmacological response. When and if tapering off buprenorphine becomes a goal, a planned, gradual taper managed by your provider minimizes withdrawal significantly.
Addiction, as defined in the DSM-5, is compulsive substance use despite negative consequences — continued use when it is harming your relationships, health, finances, and functioning. It involves loss of control. It reflects neurobiological changes to dopamine signaling and reward pathways from prior substance use.
People taking Suboxone as prescribed — going to appointments, not escalating their dose, not seeking to use it recreationally — are not addicted to it. They are medically managed. The behavior pattern that defines addiction is absent.
Why Buprenorphine’s Misuse Potential Is Lower Than Full Agonists
Not all opioids carry equal addiction risk. Several properties of buprenorphine specifically limit its misuse potential:
Partial agonism: Buprenorphine activates mu-opioid receptors only partially. It does not produce the euphoric rush that heroin, oxycodone, or fentanyl produces in opioid-naive people. Attempting to misuse it does not yield escalating euphoria — it hits a ceiling. We cover why Suboxone can make you tired in a separate article.
The ceiling effect: Above a certain dose, additional buprenorphine produces no additional opioid effect. This self-limiting property means dose escalation in pursuit of a high is pharmacologically unrewarding — and substantially reduces the overdose risk associated with escalation in full agonists.
Naloxone component: Suboxone contains naloxone specifically to deter injection misuse. Naloxone absorbs poorly through the sublingual route (the intended method of administration), but activates fully when injected — precipitating immediate withdrawal. This was a deliberate formulation decision to reduce diversion.
High receptor affinity: Buprenorphine’s tight receptor binding means it blocks the effect of illicit opioids taken on top of it, reducing the reward value of continued street drug use.
What the Evidence Shows
The scientific and medical consensus on buprenorphine maintenance treatment is not ambiguous or contested:
- Cochrane reviews (the gold standard of evidence synthesis) show buprenorphine maintenance treatment significantly reduces illicit opioid use, overdose deaths, criminal activity, and infectious disease transmission, and improves social functioning
- SAMHSA, ASAM, the CDC, and the WHO all identify MAT with buprenorphine as the evidence-based first-line treatment for opioid use disorder
- 50–60% reduction in opioid overdose mortality in patients maintained on buprenorphine compared to no medication treatment (multiple meta-analyses)
- Long-term MAT produces better outcomes than short-term. Patients who discontinue buprenorphine prematurely face elevated relapse rates and significantly increased overdose risk
The criticism that MAT “substitutes one addiction for another” ignores what the data actually shows. Physical dependence on a prescribed, monitored medication is categorically different from active opioid use disorder. A person maintaining stability on buprenorphine, functioning in their life, and not using illicit opioids is, by any clinically meaningful measure, doing well. If that applies to you, read more about how long Suboxone blocks opiates.
The Analogy That Makes This Clear
Patients with hypertension are physically dependent on their blood pressure medications. Stopping them abruptly causes dangerous rebound effects. No one argues they should discontinue their medication to avoid “dependence.”
The same principle applies to MAT. The body’s adaptation to a medication is not the same as addiction. The distinction is not a semantic game — it determines whether someone gets treatment or avoids it based on stigma.
Long-Term MAT Is Not a Failure of Recovery
For many people with opioid use disorder, long-term MAT is not a stepping stone to something else. It is the treatment itself — a medically managed life that does not revolve around obtaining, using, and recovering from illicit opioids.
ASAM recommends buprenorphine maintenance for as long as it is clinically beneficial. Some people taper off after a year or two of stability. Others remain on it long-term with excellent outcomes: employment, stable housing, intact relationships, and functional health. Both are valid treatment trajectories.
There is no clinical evidence that requiring someone to taper off buprenorphine on a predetermined timeline produces better outcomes. The opposite is true: premature discontinuation is associated with relapse and overdose. Our team also explains how to maximize Suboxone absorption in detail.
Frequently Asked Questions
Is Suboxone physically addictive?
Physical dependence develops with daily use — meaning stopping abruptly causes withdrawal. This is expected and managed through a planned taper when the time comes. Physical dependence is not the same as addiction, and the distinction is clinically important.
Can you get high on Suboxone?
Not meaningfully at prescribed doses, particularly in people with opioid tolerance. Buprenorphine’s partial agonism and ceiling effect limit its euphoric potential. The absence of euphoria at therapeutic doses is part of why it works — it treats the disorder without producing a reward cycle.
Is long-term Suboxone use safe?
Yes, based on available evidence. Long-term buprenorphine maintenance is explicitly recommended by ASAM and SAMHSA for patients who benefit from it, with outcomes data consistently favorable over both short-term and no-medication approaches.
How do I stop Suboxone when I’m ready?
Tapering off buprenorphine should be a planned, gradual process coordinated with your provider — not a cold-turkey stop. There is no requirement to taper on any timeline. If you are stable and functioning well on buprenorphine, that is a success, not a problem to solve. Learn more about taking gabapentin with Suboxone here.
If I take Suboxone, am I “really” in recovery?
Yes. Medical recovery includes stable management of a chronic condition. MAT is evidence-based treatment. Many people in long-term MAT have rebuilt careers, relationships, and health while on buprenorphine. That is what recovery looks like for them — and the data supports it.
Why do some people say Suboxone is just trading one addiction for another?
This belief conflates physical dependence with addiction and is not supported by clinical evidence. It originates from stigma, not pharmacology. Your treatment decisions should be based on what the data shows — and the data strongly supports buprenorphine maintenance.
This article is for educational purposes only. Suboxone (buprenorphine/naloxone) requires a prescription and ongoing medical supervision. Contact Trust Psychiatry & Wellness at (561) 849-4449 to discuss MAT treatment options.
Treatment That Gives You Accurate Information
People with opioid use disorder deserve clinically honest answers — not stigma wrapped in medical language. At Trust Psychiatry & Wellness in West Palm Beach, Josie Desmarais, PMHNP-BC, takes the distinction between dependence and addiction seriously in every patient conversation, and builds treatment plans around evidence, not outdated assumptions. You may also want to understand who can prescribe Suboxone.
Learn about our MAT program or call (561) 849-4449). Telehealth available statewide across Florida.
Ready to Schedule a Psychiatric Evaluation?
Reviewed by · Board-Certified Psychiatric-Mental Health Nurse Practitioner
Josie Desmarais is a board-certified psychiatric-mental health nurse practitioner (PMHNP-BC) at Trust Psychiatry – Mental Health West Palm Beach. She provides psychiatric evaluation and medication management, and helps patients understand how medication-assisted treatment supports recovery from opioid use, through secure telepsychiatry for adults across Florida.